Laëtitia Bénard
Partner – Paris
Tel +33140065033
laetitia.benard@allenovery.com
Laëtitia leads the Paris IP practice and is co-head of Allen & Overy’s Life Sciences Group worldwide. She has specific expertise in the pharmaceutical sector, where she advises client on various regulatory and contractual matters such as price regulation, advertisement for medicines, transfers of technology and anti-bribery rules.
Laëtitia was recognized by Best Lawyers as the leading Biotechnology practitioner in France. Clients observe that “she has developed profound expertise in the pharmaceutical and biotech areas, both in regulatory and contentious areas.”
Posts by: Laëtitia Bénard
- French regulator (ANSM) introduces fast-track authorisation procedures for clinical trials
- French ATU procedure simplified to ensure rapid patient access to innovations
- France publishes call for projects on incentive mechanisms to favour hospital prescription of biosimilars
- French government meets with healthcare industry at eighth meeting of the Strategic Council for the Healthcare Industries
- Rewarding innovation: pharmaceutical incentives as a crucial instrument to foster public health
- European Commission proposes export manufacturing waiver for SPCs
- France publishes list of low-interventional and non-interventional human clinical trials
- French IPO allows extension of the duration of SPCs on the basis of the MA notification date
- ANSM recommendations prohibit use of umbrella brands with respect to health products in France
- EU Competitiveness Council to review Current Status of the Unitary Patent and Unified Patent Court
- Proposals for reform of EU Paediatric Regulation postponed - EC to take another look at orphan incentives for paediatric medicines
- France one step closer to biosimilar substitution: ANSM introduces first similar biologic groups
- European Commission opens public consultation on SPCs and patent research exemptions
- ANSM publishes results of French pilot project on new EU clinical trials procedures
- New circular clarifies revised French transparency requirements
- New requirements for Temporary Authorisations for Use in France
- French Administrative Supreme Court upholds Avastin Temporary Recommendations for Use
- ANSM publishes the first year of results in the French pilot project on new EU clinical trials procedures
- France adopts stricter "anti-gift" provisions to limit conflicts of interest
- French Parliament approves expanding substitution of biosimilars
- French Parliament debates on expanding substitution of biosimilars
- ANSM opens public consultation with respect to its draft recommendations on medicinal product names
- France: Long-awaited biosimilar register created
- French Administrative Supreme Court rejects requests for annulment of Decree on Temporary Recommendations for Use
- French Minister of Health issues action plan to strengthen the safety of clinical trial volunteers
- ANSM relaxes its position on interchangeability of biosimilars
- French Competition Authority issues unfavourable opinion on draft decrees regulating online sales of medicines
- ANSM issues measures regarding first-in-human trials in wake of French trial tragedy